This “Cryptococcosis - Pipeline Insight, 2021” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Cryptococcosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cryptococcosis is caused by a fungus known as Cryptococcosis neoformans. The infection may be spread to humans through contact with pigeon droppings or unwashed raw fruit. Contact with an infected individual may also spread the infection. Individuals with disorders characterized by lowered immunity (for instance, HIV infection) are at high risk for contracting these infections. Cryptococcosis may appear in various forms depending on how the infection is acquired. In most cases, the infection begins in the lungs (pulmonary form) and may then spread to the brain, urinary tract, skin, and/or bones (disseminated form).
"Cryptococcosis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cryptococcosis pipeline landscape is provided which includes the disease overview and Cryptococcosis treatment guidelines. The assessment part of the report embraces, in depth Cryptococcosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryptococcosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Cryptococcosis R&D. The therapies under development are focused on novel approaches to treat/improve Cryptococcosis.
This segment of the Cryptococcosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MAT 2203: Matinas BioPharma
MAT2203 is an orally-administered formulation of amphotericin B (a broad spectrum fungicidal agent) utilizing Matinas' proprietary lipid nano-crystal (“LNC”) delivery technology platform. The Company's LNC delivery platform utilizes lipid nano-crystals which can encapsulate small molecules, nucleic acid polymers such as oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The drug is currently in phase 2 stage of clinical trial evaluation for the treatment of patients with Cryptococcosis.
This segment of the report provides insights about the different Cryptococcosis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 4+ key companies which are developing the therapies for Cryptococcosis. The companies which have their Cryptococcosis drug candidates in the most advanced stage, i.e. phase II include, Matinas BioPharma.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cryptococcosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cryptococcosis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cryptococcosis drugs.
Research programme: fungal infection therapies
Geography Covered
- Global coverage
Cryptococcosis Understanding
Cryptococcosis: Overview
Cryptococcosis is caused by a fungus known as Cryptococcosis neoformans. The infection may be spread to humans through contact with pigeon droppings or unwashed raw fruit. Contact with an infected individual may also spread the infection. Individuals with disorders characterized by lowered immunity (for instance, HIV infection) are at high risk for contracting these infections. Cryptococcosis may appear in various forms depending on how the infection is acquired. In most cases, the infection begins in the lungs (pulmonary form) and may then spread to the brain, urinary tract, skin, and/or bones (disseminated form).
"Cryptococcosis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cryptococcosis pipeline landscape is provided which includes the disease overview and Cryptococcosis treatment guidelines. The assessment part of the report embraces, in depth Cryptococcosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryptococcosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cryptococcosis R&D. The therapies under development are focused on novel approaches to treat/improve Cryptococcosis.
Cryptococcosis Emerging Drugs Chapters
This segment of the Cryptococcosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cryptococcosis Emerging Drugs
MAT 2203: Matinas BioPharma
MAT2203 is an orally-administered formulation of amphotericin B (a broad spectrum fungicidal agent) utilizing Matinas' proprietary lipid nano-crystal (“LNC”) delivery technology platform. The Company's LNC delivery platform utilizes lipid nano-crystals which can encapsulate small molecules, nucleic acid polymers such as oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The drug is currently in phase 2 stage of clinical trial evaluation for the treatment of patients with Cryptococcosis.
Cryptococcosis: Therapeutic Assessment
This segment of the report provides insights about the different Cryptococcosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cryptococcosis
There are approx. 4+ key companies which are developing the therapies for Cryptococcosis. The companies which have their Cryptococcosis drug candidates in the most advanced stage, i.e. phase II include, Matinas BioPharma.
Phases
This report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Cryptococcosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cryptococcosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cryptococcosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cryptococcosis drugs.
Cryptococcosis Report Insights
- Cryptococcosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cryptococcosis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cryptococcosis drugs?
- How many Cryptococcosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cryptococcosis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cryptococcosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cryptococcosis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Matinas BioPharma
- Mycovia Pharmaceuticals
- Aparna Biosciences
- FUJIFILM Toyama Chemical
- TGV Therapeutics
- Amplyx Pharmaceuticals
Key Products
- MAT 2203
- TC PMY 123
Research programme: fungal infection therapies
- ATI 2307
- MYC 053
- APX 2039
Table of Contents
IntroductionExecutive Summary
Cryptococcosis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Cryptococcosis - Analytical Perspective
Mid Stage Products
- Comparative Analysis
MAT 2203: Matinas BioPharma
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
MYC 053: TGV Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Cryptococcosis Key Companies
Cryptococcosis Key Products
Cryptococcosis- Unmet Needs
Cryptococcosis- Market Drivers and Barriers
Cryptococcosis- Future Perspectives and Conclusion
Cryptococcosis Analyst Views
Cryptococcosis Key Companies
AppendixList of Tables
Table 1 Total Products for Cryptococcosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Cryptococcosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Matinas BioPharma
- Mycovia Pharmaceuticals
- Aparna Biosciences
- FUJIFILM Toyama Chemical
- TGV Therapeutics
- Amplyx Pharmaceuticals
